Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P E Cryer

Showing results (61-70 of 233) with videos related to

Pageof 24
Sort By:
The Diabetes Educator|September 1, 1988
Hypoglycemia: the limiting factor in the management of insulin-dependent diabetes mellitusC E Havlin, P E Cryer
Progress in Biochemical Pharmacology|January 1, 1980
Plasma dose-response studies with noradrenaline and adrenaline in manW E Clutter, P E Cryer
The Journal of Clinical Investigation|April 1, 1980
Biphasic adrenergic modulation of beta-adrenergic receptors in man. Agonist-induced early increment and late decrement in beta-adrenergic receptor numberJ F Tohmeh, P E Cryer
Diabetes Care|August 1, 1993
Alanine and terbutaline in treatment of hypoglycemia in IDDMB V Wiethop, P E Cryer
The Journal of Clinical Endocrinology and Metabolism|October 1, 1974
Adrenergic modulation of growth hormone secretion in acromegaly: suppression during phentolamine and phentolamine-isoproterenol administrationP E Cryer, W H Daughaday
Diabetes Care|August 1, 1997
Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDMT Y Saleh, P E Cryer
Diabetes Care|January 1, 1983
Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrineP E Cryer, J E Gerich
Diabetes|February 1, 1991
Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humansS R Heller, P E Cryer
The American Journal of Physiology|March 1, 1991
Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemiaP J Boyle, P E Cryer
Diabetes Care|August 1, 1993
Glycemic actions of alanine and terbutaline in IDDMB V Wiethop, P E Cryer
Pageof 24

Showing results (61-70 of 233) with videos related to

Sort By:
Pageof 24
The Diabetes Educator|September 1, 1988
Hypoglycemia: the limiting factor in the management of insulin-dependent diabetes mellitusC E Havlin, P E Cryer
Progress in Biochemical Pharmacology|January 1, 1980
Plasma dose-response studies with noradrenaline and adrenaline in manW E Clutter, P E Cryer
The Journal of Clinical Investigation|April 1, 1980
Biphasic adrenergic modulation of beta-adrenergic receptors in man. Agonist-induced early increment and late decrement in beta-adrenergic receptor numberJ F Tohmeh, P E Cryer
Diabetes Care|August 1, 1993
Alanine and terbutaline in treatment of hypoglycemia in IDDMB V Wiethop, P E Cryer
The Journal of Clinical Endocrinology and Metabolism|October 1, 1974
Adrenergic modulation of growth hormone secretion in acromegaly: suppression during phentolamine and phentolamine-isoproterenol administrationP E Cryer, W H Daughaday
Diabetes Care|August 1, 1997
Alanine and terbutaline in the prevention of nocturnal hypoglycemia in IDDMT Y Saleh, P E Cryer
Diabetes Care|January 1, 1983
Relevance of glucose counterregulatory systems to patients with diabetes: critical roles of glucagon and epinephrineP E Cryer, J E Gerich
Diabetes|February 1, 1991
Reduced neuroendocrine and symptomatic responses to subsequent hypoglycemia after 1 episode of hypoglycemia in nondiabetic humansS R Heller, P E Cryer
The American Journal of Physiology|March 1, 1991
Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemiaP J Boyle, P E Cryer
Diabetes Care|August 1, 1993
Glycemic actions of alanine and terbutaline in IDDMB V Wiethop, P E Cryer
Pageof 24